| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| MINOXIDIL (has an active metabolite)
| MINOXIDIL | CARDIOVASCULAR | ORAL TOPICAL | Tmax 1 HOUR F 90 PERCENT PPB 0 PERCENT HT 4.2 HOUR SOLUBILITY SLIGHTLY SOLUBLE IN WATER | ADENOSINE TRIPHOSPHATE-SENSITIVE POTASSIUM CHANNEL (PMID15133413) | Sulfonylurea receptor 2, Kir6.2 UNIPROT O60706 ABCC9 more at DrugCentral | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| M MINOXIDIL (is an active metabolite)
| MINOXIDIL | CARDIOVASCULAR | - | ADENOSINE TRIPHOSPHATE-SENSITIVE POTASSIUM CHANNEL (PMID15133413) | Sulfonylurea receptor 2, Kir6.2 UNIPROT O60706 ABCC9 more at DrugCentral | EMA | ||||
